The University of Chicago Header Logo

Connection

Richard Schilsky to Humans

Back to Details
This is a "connection" page, showing publications Richard Schilsky has written about Humans.
Richard Schilsky
Connection Strength
2.652
Humans
  1. Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2024 Apr; 8:e2300527.
    View in: PubMed
    Score: 0.032
  2. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar; 8:e2300615.
    View in: PubMed
    Score: 0.032
  3. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb; 8:e2300513.
    View in: PubMed
    Score: 0.032
  4. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep; 7:e2300279.
    View in: PubMed
    Score: 0.031
  5. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep; 7:e2300385.
    View in: PubMed
    Score: 0.031
  6. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec; 20(6):699-707.
    View in: PubMed
    Score: 0.031
  7. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 06; 7:e2300041.
    View in: PubMed
    Score: 0.030
  8. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 04; 7:e2200609.
    View in: PubMed
    Score: 0.030
  9. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 02; 7:e2200505.
    View in: PubMed
    Score: 0.030
  10. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2022 Nov; 6:e2200191.
    View in: PubMed
    Score: 0.029
  11. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 10; 6:e2200306.
    View in: PubMed
    Score: 0.029
  12. Beyond the COVID-19 Pandemic: Sustaining and Improving Equitable Cancer Care and Research. Cancer J. 2022 Mar-Apr 01; 28(2):105-106.
    View in: PubMed
    Score: 0.028
  13. 'Strategic' development of precision cancer medicine in the United States. Mol Oncol. 2021 07; 15(7):1747-1749.
    View in: PubMed
    Score: 0.027
  14. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 08 01; 39(22):2443-2451.
    View in: PubMed
    Score: 0.026
  15. Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clin Cancer Res. 2021 05 01; 27(9):2394-2399.
    View in: PubMed
    Score: 0.026
  16. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 12; 15(6):743-750.
    View in: PubMed
    Score: 0.026
  17. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 12; 15(6):733-741.
    View in: PubMed
    Score: 0.026
  18. The National Clinical Trials Network and the cooperative groups: The road not taken. Cancer. 2020 12 01; 126(23):5008-5013.
    View in: PubMed
    Score: 0.025
  19. Progress in Cancer Research, Prevention, and Care. N Engl J Med. 2020 Sep 03; 383(10):897-900.
    View in: PubMed
    Score: 0.025
  20. Closing the Rural Cancer Care Gap: Three Institutional Approaches. JCO Oncol Pract. 2020 07; 16(7):422-430.
    View in: PubMed
    Score: 0.025
  21. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO Oncol Pract. 2020 Jul; 16(7):417-421.
    View in: PubMed
    Score: 0.025
  22. Talking the Talk About Tumor Genomic Testing. J Natl Cancer Inst. 2020 05 01; 112(5):436-437.
    View in: PubMed
    Score: 0.025
  23. Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. J Clin Oncol. 2020 02 10; 38(5):480-487.
    View in: PubMed
    Score: 0.024
  24. Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. J Oncol Pract. 2019 11; 15(11):575-583.
    View in: PubMed
    Score: 0.023
  25. Letter to the Editor: When Expertly Applied, ESMO-MCBS and ASCO Net Health Benefit Scores Usually Agree. J Natl Compr Canc Netw. 2019 04 01; 17(4):xxi.
    View in: PubMed
    Score: 0.023
  26. State of Cancer Care in America: Reflections on an Inaugural Year. J Oncol Pract. 2019 04; 15(4):163-165.
    View in: PubMed
    Score: 0.023
  27. Implementing Precision Medicine in Community-Based Oncology Programs: Three Models. J Oncol Pract. 2019 06; 15(6):325-329.
    View in: PubMed
    Score: 0.023
  28. Accelerating anticancer drug development - opportunities and trade-offs. Nat Rev Clin Oncol. 2018 12; 15(12):777-786.
    View in: PubMed
    Score: 0.022
  29. The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. J Oncol Pract. 2018 07; 14(7):e412-e420.
    View in: PubMed
    Score: 0.022
  30. A New Look at the State of Cancer Care in America. J Oncol Pract. 2018 07; 14(7):397-399.
    View in: PubMed
    Score: 0.022
  31. Reply to S.D. Lucio. J Clin Oncol. 2018 07 10; 36(20):2127.
    View in: PubMed
    Score: 0.022
  32. Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med. 2018 May 24; 378(21):2036-2044.
    View in: PubMed
    Score: 0.021
  33. A New IDEA in Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2018 03 29; 378(13):1242-1244.
    View in: PubMed
    Score: 0.021
  34. Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs? JAMA Oncol. 2018 03 01; 4(3):333-334.
    View in: PubMed
    Score: 0.021
  35. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 04 20; 36(12):1260-1265.
    View in: PubMed
    Score: 0.021
  36. The evidence framework for precision cancer medicine. Nat Rev Clin Oncol. 2018 03; 15(3):183-192.
    View in: PubMed
    Score: 0.021
  37. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017 Nov 20; 35(33):3737-3744.
    View in: PubMed
    Score: 0.021
  38. Converging on the Value of Value Frameworks. J Clin Oncol. 2017 08 20; 35(24):2732-2734.
    View in: PubMed
    Score: 0.020
  39. Reply to J.P. Jansen, A. Messori et al, and H.S.L. Jim et al. J Clin Oncol. 2017 04 01; 35(10):1134.
    View in: PubMed
    Score: 0.020
  40. Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge. J Am Coll Surg. 2017 01; 224(1):1-7.
    View in: PubMed
    Score: 0.019
  41. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol. 2016 08 20; 34(24):2925-34.
    View in: PubMed
    Score: 0.019
  42. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary. J Oncol Pract. 2016 Feb; 12(2):180-1.
    View in: PubMed
    Score: 0.018
  43. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016 Jan 10; 34(2):179-85.
    View in: PubMed
    Score: 0.018
  44. Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20.
    View in: PubMed
    Score: 0.018
  45. Integrating biomarkers in colorectal cancer trials in the West and China. Nat Rev Clin Oncol. 2015 Sep; 12(9):553-60.
    View in: PubMed
    Score: 0.017
  46. Improving evidence developed from population-level experience with targeted agents. Clin Pharmacol Ther. 2015 May; 97(5):478-87.
    View in: PubMed
    Score: 0.017
  47. Innovative clinical trials for development of personalized cancer medicine. Mol Oncol. 2015 May; 9(5):933-4.
    View in: PubMed
    Score: 0.017
  48. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015 Feb 18; 15:69.
    View in: PubMed
    Score: 0.017
  49. Moving from evaluation to value in cancer care. Clin Cancer Res. 2015 Mar 01; 21(5):947-9.
    View in: PubMed
    Score: 0.017
  50. Using Big Data to Track Trends in Medical Practice. J Oncol Pract. 2015 01; 11(1):69-70.
    View in: PubMed
    Score: 0.017
  51. Optimizing dosing of oncology drugs. Clin Pharmacol Ther. 2014 Nov; 96(5):572-9.
    View in: PubMed
    Score: 0.017
  52. Reply to F.E. Vera-Badillo et al. J Clin Oncol. 2014 Oct 01; 32(28):3198.
    View in: PubMed
    Score: 0.017
  53. ASCO's initiative to define value in cancer care. Am J Manag Care. 2014 Aug; 20(11 Spec No.):E1.
    View in: PubMed
    Score: 0.017
  54. Drivers of change in cancer care. J Oncol Pract. 2014 Sep; 10(5):315-6.
    View in: PubMed
    Score: 0.016
  55. Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ. J Clin Oncol. 2014 Aug 01; 32(22):2373-9.
    View in: PubMed
    Score: 0.016
  56. Progress against GI cancer during the American Society of Clinical Oncology's first 50 years. J Clin Oncol. 2014 May 20; 32(15):1521-30.
    View in: PubMed
    Score: 0.016
  57. Implementing personalized cancer care. Nat Rev Clin Oncol. 2014 07; 11(7):432-8.
    View in: PubMed
    Score: 0.016
  58. Precision cancer medicine: the future is now, only better. Am Soc Clin Oncol Educ Book. 2014; 61-9.
    View in: PubMed
    Score: 0.016
  59. American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol. 2013 Dec 01; 31(34):4362-70.
    View in: PubMed
    Score: 0.016
  60. Wither the cooperative groups? J Clin Oncol. 2014 Jan 20; 32(3):251-4.
    View in: PubMed
    Score: 0.016
  61. Reevaluating the accelerated approval process for oncology drugs. Clin Cancer Res. 2013 Jun 01; 19(11):2804-9.
    View in: PubMed
    Score: 0.015
  62. Publicly funded clinical trials and the future of cancer care. Oncologist. 2013; 18(2):232-8.
    View in: PubMed
    Score: 0.015
  63. Strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine. Am Soc Clin Oncol Educ Book. 2013; 118-25.
    View in: PubMed
    Score: 0.015
  64. Randomized controlled trials and comparative effectiveness research. J Clin Oncol. 2012 Dec 01; 30(34):4194-201.
    View in: PubMed
    Score: 0.015
  65. Targeted therapy for cancer: asking the right questions. Oncology (Williston Park). 2012 Oct; 26(10):947-9.
    View in: PubMed
    Score: 0.015
  66. Development and use of integral assays in clinical trials. Clin Cancer Res. 2012 Mar 15; 18(6):1540-6.
    View in: PubMed
    Score: 0.014
  67. Personalized cancer medicine - a strategy to counteract an increasing cancer challenge. Mol Oncol. 2012 Apr; 6(2):109-10.
    View in: PubMed
    Score: 0.014
  68. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol. 2011 Dec 06; 9(4):208-14.
    View in: PubMed
    Score: 0.014
  69. Using patient-initiated study participation in the development of evidence for personalized cancer therapy. Clin Cancer Res. 2011 Nov 01; 17(21):6651-7.
    View in: PubMed
    Score: 0.014
  70. Clinical trials in the era of personalized oncology. CA Cancer J Clin. 2011 Nov-Dec; 61(6):365-81.
    View in: PubMed
    Score: 0.014
  71. Update in hematology and oncology: evidence published in 2010. Ann Intern Med. 2011 Apr 05; 154(7):487-94.
    View in: PubMed
    Score: 0.013
  72. Tumor heterogeneity as the foundation of personalized cancer treatment. Semin Oncol. 2011 Apr; 38(2):171-2.
    View in: PubMed
    Score: 0.013
  73. Accrual to cancer clinical trials in the era of molecular medicine. Sci Transl Med. 2011 Mar 23; 3(75):75cm9.
    View in: PubMed
    Score: 0.013
  74. The next phase of chemoprevention research. Cancer Prev Res (Phila). 2011 Mar; 4(3):293-5.
    View in: PubMed
    Score: 0.013
  75. GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy. Nat Rev Clin Oncol. 2011 Feb; 8(2):70-2.
    View in: PubMed
    Score: 0.013
  76. Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol. 2010 Dec 01; 28(34):5046-53.
    View in: PubMed
    Score: 0.013
  77. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010 Jun; 7(6):318-25.
    View in: PubMed
    Score: 0.012
  78. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov. 2010 05; 9(5):363-6.
    View in: PubMed
    Score: 0.012
  79. Commentary: tackling the challenges of developing targeted therapies for cancer. Oncologist. 2010; 15(5):484-7.
    View in: PubMed
    Score: 0.012
  80. Data submission standards and evidence requirements. Oncologist. 2010; 15(5):488-91.
    View in: PubMed
    Score: 0.012
  81. Translating the cancer genome into clinically useful tools and strategies. Dis Model Mech. 2009 Sep-Oct; 2(9-10):426-9.
    View in: PubMed
    Score: 0.012
  82. The impact of the privacy rule on cancer research: variations in attitudes and application of regulatory standards. J Clin Oncol. 2009 Aug 20; 27(24):4014-20.
    View in: PubMed
    Score: 0.012
  83. Personalizing cancer care: American Society of Clinical Oncology presidential address 2009. J Clin Oncol. 2009 Aug 10; 27(23):3725-30.
    View in: PubMed
    Score: 0.012
  84. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009 Apr 20; 27(12):2091-6.
    View in: PubMed
    Score: 0.011
  85. Introduction: contributions of the cooperative groups. Semin Oncol. 2008 Oct; 35(5):459.
    View in: PubMed
    Score: 0.011
  86. The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics). Clin Cancer Res. 2008 Sep 15; 14(18):5685-91.
    View in: PubMed
    Score: 0.011
  87. How not to treat cancer. Lancet Oncol. 2008 Jun; 9(6):504-5.
    View in: PubMed
    Score: 0.011
  88. American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol. 2008 May 20; 26(15):2562-7.
    View in: PubMed
    Score: 0.011
  89. Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials. J Clin Oncol. 2008 Mar 10; 26(8):1371-8.
    View in: PubMed
    Score: 0.011
  90. The role of cooperative groups in cancer clinical trials. Cancer Treat Res. 2007; 132:111-29.
    View in: PubMed
    Score: 0.010
  91. Target practice: oncology drug development in the era of genomic medicine. Clin Trials. 2007; 4(2):163-6; discussion 173-7.
    View in: PubMed
    Score: 0.010
  92. A concise history of the cancer and leukemia group B. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3553s-5s.
    View in: PubMed
    Score: 0.009
  93. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s.
    View in: PubMed
    Score: 0.009
  94. First-line treatment options for patients with metastatic colorectal cancer. Nat Clin Pract Oncol. 2004 Dec; 1(2):70-1.
    View in: PubMed
    Score: 0.008
  95. Cetuximab in the treatment of colorectal cancer. Clin Adv Hematol Oncol. 2004 Nov; 2(11):1-10; quiz 11-12.
    View in: PubMed
    Score: 0.008
  96. 3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice. Expert Rev Mol Diagn. 2004 Jul; 4(4):431-3.
    View in: PubMed
    Score: 0.008
  97. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004 Mar 22; 90(6):1190-7.
    View in: PubMed
    Score: 0.008
  98. Drug development for major chronic health conditions-aligning with growing public health needs: Proceedings from a multistakeholder think tank. Am Heart J. 2024 Apr; 270:23-43.
    View in: PubMed
    Score: 0.008
  99. Are targeted therapies really targeted? Clin Adv Hematol Oncol. 2003 Dec; 1(12):722-3.
    View in: PubMed
    Score: 0.008
  100. Hurry up and wait: is accelerated approval of new cancer drugs in the best interests of cancer patients? J Clin Oncol. 2003 Oct 15; 21(20):3718-20.
    View in: PubMed
    Score: 0.008
  101. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20; 41(33):5140-5150.
    View in: PubMed
    Score: 0.008
  102. Health Data Sharing Perspectives of Patients Receiving Care in CancerLinQ-Participating Oncology Practices. JCO Oncol Pract. 2023 08; 19(8):626-636.
    View in: PubMed
    Score: 0.008
  103. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003 Mar 06; 348(10):883-90.
    View in: PubMed
    Score: 0.007
  104. Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. JCO Precis Oncol. 2022 09; 6:e2200072.
    View in: PubMed
    Score: 0.007
  105. Tumor markers as clinical cancer tests--are we there yet? Semin Oncol. 2002 Jun; 29(3):211-2.
    View in: PubMed
    Score: 0.007
  106. Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories. Clin Cancer Res. 2002 May; 8(5):943-8.
    View in: PubMed
    Score: 0.007
  107. Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation. Clin Colorectal Cancer. 2002 May; 2(1):51-2.
    View in: PubMed
    Score: 0.007
  108. End points in cancer clinical trials and the drug approval process. Clin Cancer Res. 2002 Apr; 8(4):935-8.
    View in: PubMed
    Score: 0.007
  109. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 07; 11(14):2790-2800.
    View in: PubMed
    Score: 0.007
  110. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol. 2002 Mar 15; 20(6):1519-26.
    View in: PubMed
    Score: 0.007
  111. Use of Biosimilar Medications in Oncology. JCO Oncol Pract. 2022 Mar; 18(3):177-186.
    View in: PubMed
    Score: 0.007
  112. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
    View in: PubMed
    Score: 0.007
  113. Silence is golden: gene hypermethylation and survival in large-cell lymphoma. J Natl Cancer Inst. 2002 Jan 02; 94(1):6-7.
    View in: PubMed
    Score: 0.007
  114. Patient Experiences, Trust, and Preferences for Health Data Sharing. JCO Oncol Pract. 2022 Mar; 18(3):e339-e350.
    View in: PubMed
    Score: 0.007
  115. Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncol Pract. 2022 04; 18(4):e426-e441.
    View in: PubMed
    Score: 0.007
  116. The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 10; 15(10):2507-2543.
    View in: PubMed
    Score: 0.007
  117. Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer. 2001 Aug; 1(2):95-103.
    View in: PubMed
    Score: 0.007
  118. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med. 2001 Jul 12; 345(2):144-5; author reply 146.
    View in: PubMed
    Score: 0.007
  119. What can heart failure trialists learn from oncology trialists? Eur Heart J. 2021 06 21; 42(24):2373-2383.
    View in: PubMed
    Score: 0.007
  120. Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations. Clin Cancer Res. 2021 05 01; 27(9):2430-2434.
    View in: PubMed
    Score: 0.006
  121. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group. Clin Cancer Res. 2021 05 01; 27(9):2408-2415.
    View in: PubMed
    Score: 0.006
  122. Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. J Clin Oncol. 2021 04 01; 39(10):1165-1184.
    View in: PubMed
    Score: 0.006
  123. Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. JCO Oncol Pract. 2021 01; 17(1):41-51.
    View in: PubMed
    Score: 0.006
  124. American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. J Clin Oncol. 2021 01 10; 39(2):155-169.
    View in: PubMed
    Score: 0.006
  125. Antineoplastic drugs administered during pregnancy. Semin Oncol. 2000 Dec; 27(6):618-22.
    View in: PubMed
    Score: 0.006
  126. Governance of a Learning Health Care System for Oncology: Patient Recommendations. JCO Oncol Pract. 2021 04; 17(4):e479-e489.
    View in: PubMed
    Score: 0.006
  127. The International Collaboration for Cancer Classification and Research. Int J Cancer. 2021 02 01; 148(3):560-571.
    View in: PubMed
    Score: 0.006
  128. Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. JAMA Netw Open. 2020 10 01; 3(10):e2014661.
    View in: PubMed
    Score: 0.006
  129. Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. JCO Glob Oncol. 2020 Sep; 6:1461-1471.
    View in: PubMed
    Score: 0.006
  130. Pharmacology and clinical status of capecitabine. Oncology (Williston Park). 2000 Sep; 14(9):1297-306; discussion 1309-11.
    View in: PubMed
    Score: 0.006
  131. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res. 2000 Aug; 6(8):3025-31.
    View in: PubMed
    Score: 0.006
  132. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul; 9(7):1635-49.
    View in: PubMed
    Score: 0.006
  133. Patient Preferences Regarding Informed Consent Models for Participation in a Learning Health Care System for Oncology. JCO Oncol Pract. 2020 09; 16(9):e977-e990.
    View in: PubMed
    Score: 0.006
  134. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2000 Apr; 11(4):415-20.
    View in: PubMed
    Score: 0.006
  135. Status Update on Data Required to Build a Learning Health System. J Clin Oncol. 2020 05 10; 38(14):1602-1607.
    View in: PubMed
    Score: 0.006
  136. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2020 04 01; 38(10):1081.
    View in: PubMed
    Score: 0.006
  137. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2020 03; 25(3):e405-e411.
    View in: PubMed
    Score: 0.006
  138. Effect of Public Deliberation on Patient Attitudes Regarding Consent and Data Use in a Learning Health Care System for Oncology. J Clin Oncol. 2019 12 01; 37(34):3203-3211.
    View in: PubMed
    Score: 0.006
  139. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019 10; 574(7776):127-131.
    View in: PubMed
    Score: 0.006
  140. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999 Sep; 5(9):2289-96.
    View in: PubMed
    Score: 0.006
  141. Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology. Oncologist. 2019 10; 24(10):1287-1290.
    View in: PubMed
    Score: 0.006
  142. Challenges and approaches to implementing master/basket trials in oncology. Blood Adv. 2019 07 23; 3(14):2237-2243.
    View in: PubMed
    Score: 0.006
  143. The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019 05 17; 7(1):129.
    View in: PubMed
    Score: 0.006
  144. Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise. J Clin Oncol. 2019 07 10; 37(20):1690-1694.
    View in: PubMed
    Score: 0.006
  145. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study--Cancer and Leukemia Group B 8642. J Clin Oncol. 1999 May; 17(5):1397-406.
    View in: PubMed
    Score: 0.006
  146. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758.
    View in: PubMed
    Score: 0.006
  147. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer. 1999 Mar 15; 85(6):1261-8.
    View in: PubMed
    Score: 0.006
  148. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2019 04 01; 37(10):834-849.
    View in: PubMed
    Score: 0.006
  149. Immunotherapy for colorectal cancer. Curr Oncol Rep. 1999; 1(2):147-8.
    View in: PubMed
    Score: 0.006
  150. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. J Clin Oncol. 2019 02 01; 37(4):336-349.
    View in: PubMed
    Score: 0.006
  151. Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. J Clin Oncol. 2019 01 01; 37(1):72-80.
    View in: PubMed
    Score: 0.006
  152. Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. J Immunother Cancer. 2018 10 19; 6(1):108.
    View in: PubMed
    Score: 0.006
  153. Biochemical and clinical pharmacology of 5-fluorouracil. Oncology (Williston Park). 1998 Oct; 12(10 Suppl 7):13-8.
    View in: PubMed
    Score: 0.006
  154. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 09; 100:35-45.
    View in: PubMed
    Score: 0.005
  155. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998 May; 16(5):1811-9.
    View in: PubMed
    Score: 0.005
  156. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7.
    View in: PubMed
    Score: 0.005
  157. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Arch Pathol Lab Med. 2018 10; 142(10):1242-1253.
    View in: PubMed
    Score: 0.005
  158. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018 06 01; 36(16):1631-1641.
    View in: PubMed
    Score: 0.005
  159. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044.
    View in: PubMed
    Score: 0.005
  160. Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. J Clin Oncol. 2018 02 20; 36(6):617-623.
    View in: PubMed
    Score: 0.005
  161. Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. Cell. 2017 Nov 16; 171(5):982-986.
    View in: PubMed
    Score: 0.005
  162. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. Clin Cancer Res. 1997 Nov; 3(11):1977-84.
    View in: PubMed
    Score: 0.005
  163. Global Challenges for Cancer Imaging. J Glob Oncol. 2018 09; 4:1-10.
    View in: PubMed
    Score: 0.005
  164. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
    View in: PubMed
    Score: 0.005
  165. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Clin Cancer Res. 1997 May; 3(5):719-25.
    View in: PubMed
    Score: 0.005
  166. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367.
    View in: PubMed
    Score: 0.005
  167. Reply to L. Casadaban et al. J Clin Oncol. 2017 04 20; 35(12):1373-1374.
    View in: PubMed
    Score: 0.005
  168. Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541. J Clin Oncol. 1996 Nov; 14(11):3000-8.
    View in: PubMed
    Score: 0.005
  169. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1452-1459.
    View in: PubMed
    Score: 0.005
  170. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. J Clin Oncol. 2016 11 10; 34(32):3872-3879.
    View in: PubMed
    Score: 0.005
  171. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol. 2016 11 20; 34(33):3992-3999.
    View in: PubMed
    Score: 0.005
  172. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). J Clin Oncol. 2016 09 01; 34(25):3047-53.
    View in: PubMed
    Score: 0.005
  173. Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel. J Clin Oncol. 1996 Jun; 14(6):1964-5.
    View in: PubMed
    Score: 0.005
  174. Transformation of Health Care - Perspectives of Opinion Leaders. Semin Oncol Nurs. 2016 05; 32(2):172-82.
    View in: PubMed
    Score: 0.005
  175. Response. J Natl Cancer Inst. 2016 Mar; 108(3):djw001.
    View in: PubMed
    Score: 0.005
  176. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20; 34(9):987-1011.
    View in: PubMed
    Score: 0.005
  177. Methotrexate: an effective agent for treating cancer and building careers. The polyglutamate era. Stem Cells. 1996 Jan; 14(1):29-32.
    View in: PubMed
    Score: 0.005
  178. Adjuvant therapy of colon cancer. Semin Oncol. 1995 Dec; 22(6):600-10.
    View in: PubMed
    Score: 0.005
  179. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11).
    View in: PubMed
    Score: 0.004
  180. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol. 1995 Sep; 13(9):2230-7.
    View in: PubMed
    Score: 0.004
  181. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25.
    View in: PubMed
    Score: 0.004
  182. American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. J Clin Oncol. 2015 Aug 10; 33(23):2563-77.
    View in: PubMed
    Score: 0.004
  183. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Jun 10; 6(16):14139-52.
    View in: PubMed
    Score: 0.004
  184. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug; 33(4):901-10.
    View in: PubMed
    Score: 0.004
  185. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015 Aug; 26(8):1791-8.
    View in: PubMed
    Score: 0.004
  186. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7.
    View in: PubMed
    Score: 0.004
  187. Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology. Cancer Epidemiol Biomarkers Prev. 2015 Mar; 24(3):484-9.
    View in: PubMed
    Score: 0.004
  188. Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst. 2015 Apr; 107(4).
    View in: PubMed
    Score: 0.004
  189. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
    View in: PubMed
    Score: 0.004
  190. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. J Clin Oncol. 1994 Dec; 12(12):2743-50.
    View in: PubMed
    Score: 0.004
  191. Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). J Natl Cancer Inst. 2015 Jan; 107(1):336.
    View in: PubMed
    Score: 0.004
  192. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014 Aug 20; 32(24):2587-94.
    View in: PubMed
    Score: 0.004
  193. Reply to L.k. Griffeth et al and J.E. Battley et al. J Clin Oncol. 2014 Sep 01; 32(25):2812-3.
    View in: PubMed
    Score: 0.004
  194. Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol. 2014 Aug 01; 32(22):2328-34.
    View in: PubMed
    Score: 0.004
  195. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014 Apr 20; 32(12):1277-80.
    View in: PubMed
    Score: 0.004
  196. Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemother Pharmacol. 1994; 34(6):509-14.
    View in: PubMed
    Score: 0.004
  197. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014 Jan; 15(1):e8-21.
    View in: PubMed
    Score: 0.004
  198. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study. J Natl Cancer Inst. 1993 Aug 18; 85(16):1319-26.
    View in: PubMed
    Score: 0.004
  199. Breaking a vicious cycle. Sci Transl Med. 2013 Jul 31; 5(196):196cm6.
    View in: PubMed
    Score: 0.004
  200. Update on biochemical modulation of chemotherapeutic agents. Oncology (Williston Park). 1993 May; 7(5):99-106, 109; discussion 110-4, 117.
    View in: PubMed
    Score: 0.004
  201. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
    View in: PubMed
    Score: 0.004
  202. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10; 31(14):1775-81.
    View in: PubMed
    Score: 0.004
  203. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. Cancer Res. 1993 Mar 15; 53(6):1293-6.
    View in: PubMed
    Score: 0.004
  204. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol. 2013 Mar 20; 31(9):1134-9.
    View in: PubMed
    Score: 0.004
  205. Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993; 31(4):283-8.
    View in: PubMed
    Score: 0.004
  206. Antifolates: the next generation. Semin Oncol. 1992 Dec; 19(6):707-19.
    View in: PubMed
    Score: 0.004
  207. Prospects for fertility after cancer chemotherapy. Semin Oncol. 1992 Oct; 19(5):597-604.
    View in: PubMed
    Score: 0.004
  208. Biochemical pharmacology of chemotherapeutic drugs used as radiation enhancers. Semin Oncol. 1992 Aug; 19(4 Suppl 11):2-7.
    View in: PubMed
    Score: 0.004
  209. Laboratory and clinical studies of biochemical modulation by hydroxyurea. Semin Oncol. 1992 Jun; 19(3 Suppl 9):84-9.
    View in: PubMed
    Score: 0.004
  210. Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst. 2012 Apr 18; 104(8):581-9.
    View in: PubMed
    Score: 0.004
  211. Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5.
    View in: PubMed
    Score: 0.003
  212. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84.
    View in: PubMed
    Score: 0.003
  213. Phase II study of echinomycin in patients with advanced breast cancer: a report of Cancer and Leukemia Group B protocol 8641. Invest New Drugs. 1991 Aug; 9(3):269-72.
    View in: PubMed
    Score: 0.003
  214. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. J Clin Oncol. 2011 Jun 01; 29(16):2282-90.
    View in: PubMed
    Score: 0.003
  215. WIN Consortium--challenges and advances. Nat Rev Clin Oncol. 2011 Mar; 8(3):133-4.
    View in: PubMed
    Score: 0.003
  216. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9.
    View in: PubMed
    Score: 0.003
  217. An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov. 2011 02; 10(2):79-80.
    View in: PubMed
    Score: 0.003
  218. A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. Eur J Cancer. 1991; 27(2):217-8.
    View in: PubMed
    Score: 0.003
  219. Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study. Cancer Chemother Pharmacol. 1991; 28(1):69-73.
    View in: PubMed
    Score: 0.003
  220. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist. 2010; 15(12):1310-9.
    View in: PubMed
    Score: 0.003
  221. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol. 1990 Dec; 8(12):2054-61.
    View in: PubMed
    Score: 0.003
  222. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.003
  223. Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst. 1990 Sep 05; 82(17):1411-5.
    View in: PubMed
    Score: 0.003
  224. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 01; 28(22):3617-22.
    View in: PubMed
    Score: 0.003
  225. Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med. 2010 Apr 21; 2(28):28cm13.
    View in: PubMed
    Score: 0.003
  226. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol. 2010 May 20; 28(15):2635-40.
    View in: PubMed
    Score: 0.003
  227. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010 Mar 01; 16(5):1384-90.
    View in: PubMed
    Score: 0.003
  228. Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program. J Clin Oncol. 2010 Feb 01; 28(4):527-30.
    View in: PubMed
    Score: 0.003
  229. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol. 1989 Oct; 16(5):425-36.
    View in: PubMed
    Score: 0.003
  230. Infertility in patients with testicular cancer: testis, tumor, or treatment? J Natl Cancer Inst. 1989 Aug 16; 81(16):1204-5.
    View in: PubMed
    Score: 0.003
  231. Nonmalignant complications of therapy for Hodgkin's disease. Hematol Oncol Clin North Am. 1989 Jun; 3(2):331-43.
    View in: PubMed
    Score: 0.003
  232. Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing. Cancer. 1989 Mar 15; 63(6 Suppl):1018-21.
    View in: PubMed
    Score: 0.003
  233. Male fertility following cancer chemotherapy. J Clin Oncol. 1989 Mar; 7(3):295-7.
    View in: PubMed
    Score: 0.003
  234. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26.
    View in: PubMed
    Score: 0.003
  235. Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. Semin Oncol. 2008 Oct; 35(5):470-83.
    View in: PubMed
    Score: 0.003
  236. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol. 2008 Nov 01; 26(31):5043-51.
    View in: PubMed
    Score: 0.003
  237. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar; 46(3):303-8.
    View in: PubMed
    Score: 0.003
  238. Effects of cancer treatment on the reproductive system. Crit Rev Oncol Hematol. 1988; 8(2):153-71.
    View in: PubMed
    Score: 0.003
  239. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2008 Jan 10; 26(2):313-25.
    View in: PubMed
    Score: 0.003
  240. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987 Dec; 5(12):2017-31.
    View in: PubMed
    Score: 0.003
  241. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol. 2008 Jan; 15(1):158-64.
    View in: PubMed
    Score: 0.003
  242. Drug safety and drug efficacy: two sides of the same coin. Clin Cancer Res. 2007 May 01; 13(9):2533-4.
    View in: PubMed
    Score: 0.002
  243. FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol. 2007 Mar; 14(3):330-9.
    View in: PubMed
    Score: 0.002
  244. Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma. J Clin Oncol. 1987 Mar; 5(3):419-25.
    View in: PubMed
    Score: 0.002
  245. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2007 Nov; 60(6):811-9.
    View in: PubMed
    Score: 0.002
  246. Gonadal and sexual function in male patients with hairy cell leukemia: lack of adverse effects of recombinant alpha 2-interferon treatment. Cancer Treat Rep. 1987 Feb; 71(2):179-81.
    View in: PubMed
    Score: 0.002
  247. Clinical implications of tumor heterogeneity. Haematol Blood Transfus. 1987; 31:278-82.
    View in: PubMed
    Score: 0.002
  248. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2007 Jan 01; 25(1):146-62.
    View in: PubMed
    Score: 0.002
  249. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol. 2006 Oct 01; 24(28):4553-7.
    View in: PubMed
    Score: 0.002
  250. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006 Sep 20; 98(18):1335-8.
    View in: PubMed
    Score: 0.002
  251. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities. Cancer Res. 1986 Sep; 46(9):4874.
    View in: PubMed
    Score: 0.002
  252. Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer. Cancer Res. 1986 Aug; 46(8):4184-8.
    View in: PubMed
    Score: 0.002
  253. Evaluation of cognition in cancer patients: special focus on the elderly. Crit Rev Oncol Hematol. 2006 Dec; 60(3):242-55.
    View in: PubMed
    Score: 0.002
  254. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006 Aug 01; 24(22):3535-41.
    View in: PubMed
    Score: 0.002
  255. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006 Feb; 33(1):15-49.
    View in: PubMed
    Score: 0.002
  256. Tumor cell heterogeneity: implications for clinical practice. Semin Oncol. 1985 Sep; 12(3):203-6.
    View in: PubMed
    Score: 0.002
  257. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20; 97(14):1080-3.
    View in: PubMed
    Score: 0.002
  258. Cytarabine-cis-platin interactions in patients with advanced cancer. Semin Oncol. 1985 Jun; 12(2 Suppl 3):171-6.
    View in: PubMed
    Score: 0.002
  259. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005 Jun; 16(6):958-65.
    View in: PubMed
    Score: 0.002
  260. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005 Apr 01; 23(10):2191-200.
    View in: PubMed
    Score: 0.002
  261. Insulin effects on methotrexate polyglutamate synthesis and enzyme binding in cultured human breast cancer cells. Cancer Chemother Pharmacol. 1985; 15(3):272-7.
    View in: PubMed
    Score: 0.002
  262. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.
    View in: PubMed
    Score: 0.002
  263. A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin Pharmacol Ther. 2004 Nov; 76(5):490-502.
    View in: PubMed
    Score: 0.002
  264. Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer. Cancer Treat Rep. 1984 Sep; 68(9):1097-102.
    View in: PubMed
    Score: 0.002
  265. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8.
    View in: PubMed
    Score: 0.002
  266. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res. 2004 Jun 01; 10(11):3881-4.
    View in: PubMed
    Score: 0.002
  267. Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res. 2004 Jun 01; 10(11):3908-18.
    View in: PubMed
    Score: 0.002
  268. Oncology physician and nurse practices and attitudes regarding offering clinical trial results to study participants. J Natl Cancer Inst. 2004 Apr 21; 96(8):629-32.
    View in: PubMed
    Score: 0.002
  269. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2584-6.
    View in: PubMed
    Score: 0.002
  270. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7.
    View in: PubMed
    Score: 0.002
  271. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65.
    View in: PubMed
    Score: 0.002
  272. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83.
    View in: PubMed
    Score: 0.002
  273. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15; 21(8):1431-9.
    View in: PubMed
    Score: 0.002
  274. Synthesis, binding and intracellular retention of methotrexate polyglutamates by cultured human breast cancer cells. Adv Exp Med Biol. 1983; 163:247-57.
    View in: PubMed
    Score: 0.002
  275. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
    View in: PubMed
    Score: 0.002
  276. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002. Clin Colorectal Cancer. 2002 Nov; 2(3):140-5.
    View in: PubMed
    Score: 0.002
  277. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep. 1982 Sep; 66(9):1767-9.
    View in: PubMed
    Score: 0.002
  278. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans. Cancer Res. 1982 Apr; 42(4):1582-6.
    View in: PubMed
    Score: 0.002
  279. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002 Apr; 13(4):566-75.
    View in: PubMed
    Score: 0.002
  280. Renal and metabolic toxicities of cancer chemotherapy. Semin Oncol. 1982 Mar; 9(1):75-83.
    View in: PubMed
    Score: 0.002
  281. Construct validity of medicare chemotherapy claims: the case of 5FU. Med Care. 2002 Mar; 40(3):201-11.
    View in: PubMed
    Score: 0.002
  282. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402.
    View in: PubMed
    Score: 0.002
  283. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol. 2002 Jan; 13(1):87-91.
    View in: PubMed
    Score: 0.002
  284. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2(1):43-7.
    View in: PubMed
    Score: 0.002
  285. High dose cyclophosphamide plus recombinant human granulocyte-colony stimulating factor (rhG-CSF) in the treatment of follicular, low grade non-Hodgkin's lymphoma: CALGB 9150. Leuk Lymphoma. 2001 Nov-Dec; 42(6):1255-64.
    View in: PubMed
    Score: 0.002
  286. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med. 1981 Oct; 71(4):552-6.
    View in: PubMed
    Score: 0.002
  287. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
    View in: PubMed
    Score: 0.002
  288. Characteristics of membrane transport of methotrexate by cultured human breast cancer cells. Biochem Pharmacol. 1981 Jun 15; 30(12):1537-42.
    View in: PubMed
    Score: 0.002
  289. High-pressure liquid chromatography analysis of methotrexate polyglutamates in cultured human breast cancer cells. Biochem Pharmacol. 1981 Jun 01; 30(11):1387-90.
    View in: PubMed
    Score: 0.002
  290. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90.
    View in: PubMed
    Score: 0.002
  291. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr 01; 91(7):1256-63.
    View in: PubMed
    Score: 0.002
  292. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol. 2001 Mar 01; 19(5):1476-84.
    View in: PubMed
    Score: 0.002
  293. Clinical pharmacology of methotrexate. Cancer Treat Rep. 1981; 65 Suppl 1:51-4.
    View in: PubMed
    Score: 0.002
  294. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2000 Aug; 18(15):2894-901.
    View in: PubMed
    Score: 0.002
  295. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980 Jul; 93(1):109-14.
    View in: PubMed
    Score: 0.002
  296. Methotrexate polyglutamate synthesis by cultured human breast cancer cells. Proc Natl Acad Sci U S A. 1980 May; 77(5):2919-22.
    View in: PubMed
    Score: 0.002
  297. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979 Jun; 90(6):929-31.
    View in: PubMed
    Score: 0.001
  298. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs. 1999; 17(1):97-101.
    View in: PubMed
    Score: 0.001
  299. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study. J Clin Oncol. 1998 Oct; 16(10):3302-9.
    View in: PubMed
    Score: 0.001
  300. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol. 1998 Sep; 9(9):1035-7.
    View in: PubMed
    Score: 0.001
  301. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10.
    View in: PubMed
    Score: 0.001
  302. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34.
    View in: PubMed
    Score: 0.001
  303. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol. 1998 Jan; 16(1):19-26.
    View in: PubMed
    Score: 0.001
  304. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7.
    View in: PubMed
    Score: 0.001
  305. Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs. 1998-1999; 16(3):275-8.
    View in: PubMed
    Score: 0.001
  306. Adjuvant therapy for colorectal cancer. Curr Probl Surg. 1997 Aug; 34(8):601-76.
    View in: PubMed
    Score: 0.001
  307. Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule. Ann Oncol. 1997 Aug; 8(8):807-9.
    View in: PubMed
    Score: 0.001
  308. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32.
    View in: PubMed
    Score: 0.001
  309. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol. 1996 Oct; 14(10):2674-81.
    View in: PubMed
    Score: 0.001
  310. Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59.
    View in: PubMed
    Score: 0.001
  311. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics. 1996 Feb; 6(1):93-101.
    View in: PubMed
    Score: 0.001
  312. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer. 1994 Oct 01; 74(7):1965-73.
    View in: PubMed
    Score: 0.001
  313. A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 1994 Jul 01; 74(1):168-73.
    View in: PubMed
    Score: 0.001
  314. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst. 1994 Mar 02; 86(5):368-72.
    View in: PubMed
    Score: 0.001
  315. Phase II study of fludarabine phosphate for gastric adenocarcinoma. An Illinois Cancer Center trial. Invest New Drugs. 1994; 12(2):163-6.
    View in: PubMed
    Score: 0.001
  316. Phase II study of amonafide in gastric adenocarcinoma. An Illinois Cancer Center trial. Invest New Drugs. 1994; 12(3):267-70.
    View in: PubMed
    Score: 0.001
  317. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Cancer Res. 1994 Jan 01; 54(1):114-9.
    View in: PubMed
    Score: 0.001
  318. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20; 85(20):1637-43.
    View in: PubMed
    Score: 0.001
  319. Modulation of vinblastine resistance with cyclosporine: a phase I study. Clin Pharmacol Ther. 1993 Oct; 54(4):421-9.
    View in: PubMed
    Score: 0.001
  320. 5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. Ann Oncol. 1993 Aug; 4(7):591-5.
    View in: PubMed
    Score: 0.001
  321. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8.
    View in: PubMed
    Score: 0.001
  322. Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study. Cancer Chemother Pharmacol. 1993; 32(5):347-52.
    View in: PubMed
    Score: 0.001
  323. Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol. 1992 Jun; 19(3 Suppl 9):53-8.
    View in: PubMed
    Score: 0.001
  324. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther. 1991 Nov; 50(5 Pt 1):573-9.
    View in: PubMed
    Score: 0.001
  325. Cytosine arabinoside and cisplatin for advanced breast cancer. A phase II study of the Cancer and Leukemia Group B. Cancer. 1991 Oct 15; 68(8):1696-8.
    View in: PubMed
    Score: 0.001
  326. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol. 1991 Aug; 9(8):1480-6.
    View in: PubMed
    Score: 0.001
  327. Vascular events in patients receiving high-dose infusional 5-fluorouracil-based chemotherapy: the University of Chicago experience. Med Pediatr Oncol. 1991; 19(1):8-15.
    View in: PubMed
    Score: 0.001
  328. Pharmacodynamics in cancer therapy. J Clin Oncol. 1990 Oct; 8(10):1739-53.
    View in: PubMed
    Score: 0.001
  329. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report. Invest New Drugs. 1990 May; 8(2):221-6.
    View in: PubMed
    Score: 0.001
  330. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1990 Feb; 8(2):241-7.
    View in: PubMed
    Score: 0.001
  331. Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B. Med Pediatr Oncol. 1990; 18(3):197-202.
    View in: PubMed
    Score: 0.001
  332. Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study. Cancer Invest. 1990; 8(5):451-8.
    View in: PubMed
    Score: 0.001
  333. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989 Jun; 7(6):761-8.
    View in: PubMed
    Score: 0.001
  334. Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989 Mar 15; 63(6 Suppl):1048-53.
    View in: PubMed
    Score: 0.001
  335. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther. 1989 Mar; 45(3):226-33.
    View in: PubMed
    Score: 0.001
  336. A randomized study of inpatient versus outpatient continuous intravenous infusion chemotherapy: psychosocial aspects. Sel Cancer Ther. 1989; 5(3):137-45.
    View in: PubMed
    Score: 0.001
  337. A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer. 1989 Jan 01; 63(1):30-6.
    View in: PubMed
    Score: 0.001
  338. Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. J Natl Cancer Inst. 1988 Nov 02; 80(17):1412-6.
    View in: PubMed
    Score: 0.001
  339. Synergistic cytotoxicity and DNA strand break formation by bromodeoxyuridine and bleomycin in human tumor cells. Cancer Res. 1988 Aug 01; 48(15):4244-9.
    View in: PubMed
    Score: 0.001
  340. Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res. 1988 Jul 15; 48(14):4127-30.
    View in: PubMed
    Score: 0.001
  341. Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results. Otolaryngol Head Neck Surg. 1988 Apr; 98(4):295-8.
    View in: PubMed
    Score: 0.001
  342. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol. 1988 Apr; 6(4):618-26.
    View in: PubMed
    Score: 0.001
  343. The role of high-dose therapy and autologous bone marrow reinfusion in the treatment of malignant lymphomas. Cancer Invest. 1988; 6(4):427-37.
    View in: PubMed
    Score: 0.001
  344. Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6.
    View in: PubMed
    Score: 0.001
  345. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res. 1987 Apr 01; 47(7):1952-6.
    View in: PubMed
    Score: 0.001
  346. The synthesis and retention of methotrexate polyglutamates in cultured human breast cancer cells. Ann N Y Acad Sci. 1982 Dec 10; 397:184-92.
    View in: PubMed
    Score: 0.000
  347. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest. 1982 Aug; 70(2):351-60.
    View in: PubMed
    Score: 0.000
  348. Gallium-67 scanning: limited usefulness in staging patients with non-Hodgkin's lymphoma. Am J Med. 1980 May; 68(5):695-700.
    View in: PubMed
    Score: 0.000
  349. Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined Modality Trial. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1687-92.
    View in: PubMed
    Score: 0.000
  350. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1527-31.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.